期刊文献+

烟酸注射液致新的药品不良反应两例 被引量:4

Two cases of new adverse drug reactions caused by niacin injection
下载PDF
导出
摘要 1病例资料1.1病例1患者,男,52岁,体检发现“冠状动脉钙化4 d”收治入上海中医药大学附属第七人民医院,诊断为冠状动脉粥样硬化性心脏病。患者既往有高血压病史多年,血压(BP)最高150/95 mm Hg。2018-06-12辅助检查总胆固醇5.44 mmol/L,三酰甘油2.56 mmol/L↑,高密度脂蛋白胆固醇1.08 mmol/L,低密度脂蛋白胆固醇3.42 mmol/L↑,小而密低密度脂蛋白胆固醇504.4 mg/L,载脂蛋白B 1.19 g/L↑,载脂蛋白C 276.8 mg/L↑,载脂蛋白C 3131.7 mg/L↑,于2018-06-13上午9:00予烟酸注射液(广州白云山明兴制药有限公司,批号180301)100 mg+0.9%氯化钠注射液250 ml,qd,ivgtt,用于降血脂治疗及营养心肌。患者静脉补液后3 min左右突然出现心慌,伴大汗淋漓和濒死感,立即停药后症状明显好转。2018-06-14查房,患者一般状况可,未诉明显胸闷、胸痛等不适,查BP 130/80 mm Hg,生命体征平稳。
作者 李洁 张海燕 LI Jie;ZHANG Haiyan
出处 《药学服务与研究》 CAS 2019年第6期479-480,共2页 Pharmaceutical Care and Research
  • 相关文献

参考文献3

二级参考文献36

  • 1Anja Vogt, Ursula Kassner, Ulrike Hostalek, et al. Prolonged - release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study [ J ]. vascular health and risk management ,2007,3 ( 4 ) :467- 479.
  • 2Goldberg A, Alagona PJ, Capuzzi DM, et al. Multiple - dose efficacy and safety of an extended - release form of niacin in the management of hyperlipidemia [ J ]. Am J Cardiol,2000,85 (9) : 1100- 1105.
  • 3Guyton JR, Blazing MA, Hagar J, et al. Extended - release niacin vs. gemfibrozil for the treatment of low levels of high - density lipoprotein cholesterol. Niaspan - Gemfibrozil Study Group [ J ]. Arch Intern Med ,2000,160 ( 8 ) : 1177- 1184.
  • 4Birjmohun RS, Hutten BA, Kastelein JJ,et al. Efficacy and safety of high - density lipoprotein cholesterol - increasing compounds : a meta- analysis of randomized controlled trials[J]. J Am Coil Cardiol, 2005,45(2) :185- 197.
  • 5McKenney JM, McCormick LS, Schaefer EJ, et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia[ J]. Am J Cardiol,2001,88 ( 3 ) :270- 274.
  • 6Alrasadi K, Awan Z, Alwaili K, et al. Comparison of treatment of severe high - density lipoprotein cholesterol deficiency in men with daily atorvastatin (20mg) versus fenofibrate (200mg) versus extended-release niacin (2g) [J]. Am J Cardiol,2008,102(10): 1341-1347.
  • 7Kashyap ML, Mcgovern ME, Berra K, et al. Long - term safety and efficacy of a once - daily niacin/lovastatin formulation for patients with dyslipidemia [ J ]. Am J Cardiol, 2002,89 ( 6 ) : 672- 678.
  • 8Karas RH,Kashyap ML, Knopp RH, et al. Long -term safety and efficacy of a combination of niacin extended release and simvastatin n patients with dyslipidemia: the OCEANS study[J]. Am J Cardiovase Drugs, 2008,8 ( 2 ) : 69- 81.
  • 9McKenney JM ,Jones PH, Bays HE, et al. Comparative effects on lip d levels of combination therapy with a statin and extended - release niacin or ezetimibe versus a statin alone ( the COMPELL study) [ J ]. Atherosclerosis ,2007,192 ( 2 ) :432- 437.
  • 10Peter Alagona Jr. Beyond LDL cholesterol: the role of eievated triglycerides and low HDL cholesterol in residual CVD risk remaining afer statin therapy[ J]. Am J Manag care. 2009,15 :S65- S73.

共引文献32

同被引文献25

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部